Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 single ascending dose in healthy volunteers
NCT02228733Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ocederenone in hypertension (HTN) and nephropathy (6 arms), sponsored by KBP Biosciences. Primary endpoints: Safety and Tolerability at 14 days and Area Under Curve at 14 days. Started Jun 2014; status: completed.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)nephropathy
Beyond the preview
Go deeper on NCT02228733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228733.